C K Osborne

Summary

Affiliation: University of Texas Health Science Center
Country: USA

Publications

  1. ncbi request reprint Steroid hormone receptors in breast cancer management
    C K Osborne
    Department of Medicine, University of Texas Health Science Center at San Antonio 78284 7884, USA
    Breast Cancer Res Treat 51:227-38. 1998
  2. ncbi request reprint HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer
    S M Townson
    Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 6:3788-96. 2000
  3. ncbi request reprint Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo
    A V Lee
    Department of Medicine, University of Texas Health Science Center at San Antonio 78284 7884, USA
    Mol Endocrinol 13:787-96. 1999
  4. ncbi request reprint Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer
    G M Clark
    Department of Medicine, Division of Medical Oncology, University of Texas Health Science Center, San Antonio 78284, USA
    Cancer Res 57:5505-8. 1997
  5. ncbi request reprint Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions
    H H Zhao
    Division of Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78284, USA
    J Biol Chem 276:27907-12. 2001
  6. ncbi request reprint Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth
    S Oesterreich
    Breast Center, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Cancer Res 61:5771-7. 2001
  7. pmc Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
    C K Osborne
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Br J Cancer 90:S2-6. 2004
  8. ncbi request reprint Time-dependence of hazard ratios for prognostic factors in primary breast cancer
    S G Hilsenbeck
    Department of Medicine, University of Texas Health Science Center at San Antonio, 78284 7884, USA
    Breast Cancer Res Treat 52:227-37. 1998
  9. ncbi request reprint Telomerase activity and survival of patients with node-positive breast cancer
    G M Clark
    Department of Medicine, The University of Texas Health Science Center at San Antonio, 78284 7884, USA
    J Natl Cancer Inst 89:1874-81. 1997
  10. ncbi request reprint Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation
    S Oesterreich
    Department of Medicine, University of Texas Health Science Center, San Antonio 78284, USA
    Mol Endocrinol 14:369-81. 2000

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Steroid hormone receptors in breast cancer management
    C K Osborne
    Department of Medicine, University of Texas Health Science Center at San Antonio 78284 7884, USA
    Breast Cancer Res Treat 51:227-38. 1998
    ..In summary, ER and PR status are important biomarkers that help physicians individualize therapy...
  2. ncbi request reprint HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer
    S M Townson
    Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 6:3788-96. 2000
    ..We conclude that HET/SAF-B plays an important role in breast cancer, and we discuss possible mechanisms of the involvement of HET/SAF-B in cell proliferation and division...
  3. ncbi request reprint Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo
    A V Lee
    Department of Medicine, University of Texas Health Science Center at San Antonio 78284 7884, USA
    Mol Endocrinol 13:787-96. 1999
    ..Taken together, these data not only reinforce the concept of cross-talk between IGF- and ER-signaling pathways, but indicate that IGF molecules may be critical regulators of estrogen-mediated growth and breast cancer pathogenesis...
  4. ncbi request reprint Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer
    G M Clark
    Department of Medicine, Division of Medical Oncology, University of Texas Health Science Center, San Antonio 78284, USA
    Cancer Res 57:5505-8. 1997
    ..These preliminary results suggest that mitosin as assessed by IHC may be superior to SPF as a prognostic factor in node-negative breast cancer, but additional studies are necessary to validate these promising findings...
  5. ncbi request reprint Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions
    H H Zhao
    Division of Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78284, USA
    J Biol Chem 276:27907-12. 2001
    ..Therefore, FKHR represents a bifunctional NR intermediary protein that can act as either a coactivator or corepressor, depending on the receptor type...
  6. ncbi request reprint Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth
    S Oesterreich
    Breast Center, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Cancer Res 61:5771-7. 2001
    ..These data show that ERalpha is a critical requirement for IGF signaling, and to our knowledge this is the first report of functional ERalpha expression that confers estrogen-mediated growth of an ER-negative breast cancer cell line...
  7. pmc Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
    C K Osborne
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Br J Cancer 90:S2-6. 2004
    ..Preclinical and clinical study data are presented in support of the novel mechanism of action of this new type of ER antagonist...
  8. ncbi request reprint Time-dependence of hazard ratios for prognostic factors in primary breast cancer
    S G Hilsenbeck
    Department of Medicine, University of Texas Health Science Center at San Antonio, 78284 7884, USA
    Breast Cancer Res Treat 52:227-37. 1998
    ..Failure to recognize violations of proportional hazards can lead to both over- and under-estimation of the effects of important prognostic factors...
  9. ncbi request reprint Telomerase activity and survival of patients with node-positive breast cancer
    G M Clark
    Department of Medicine, The University of Texas Health Science Center at San Antonio, 78284 7884, USA
    J Natl Cancer Inst 89:1874-81. 1997
    ....
  10. ncbi request reprint Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation
    S Oesterreich
    Department of Medicine, University of Texas Health Science Center, San Antonio 78284, USA
    Mol Endocrinol 14:369-81. 2000
    ..Furthermore, our data showing that HET/SAF-B binds to ER particularly strongly in the presence of tamoxifen suggests that it may be important for the antagonist effect of tamoxifen...